AF
ACET icon

Amalgamated Financial’s Adicet Bio ACET Stock Holding History

Amalgamated Financial’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$51K Buy
+158
New +$36.3K ﹤0.01% 2417

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Amalgamated Financial's ACET Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Adicet Bio (ACET) in Q1 2022: 158 shares worth $51K. The stake represents ﹤0.01% of the portfolio and ranks #2417 among its holdings.

87 funds tracked by Wall St. Rank hold ACET as of Q1 2022.

  • Amalgamated Financial held 158 shares of Adicet Bio worth $51K as of Q1 2022.
  • Adicet Bio was a new Amalgamated Financial position in Q1 2022.
  • Adicet Bio made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2417 holding.
  • 87 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.